肝细胞癌并肺转移的治疗研究进展

摘要
图/表
参考文献(38)
相关文章 (7)

全文: PDF (0 KB) HTML (55 KB)
输出: BibTeX | EndNote (RIS)

摘要肝细胞癌（HCC）是世界上常见的恶性肿瘤之一，肺转移为最常见的远处转移。一旦发生肺转移，病情发展恶化迅速，常加快死亡速度。本文对肝细胞癌肺转移的治疗方法包括外科手术治疗、化疗药物治疗、放疗、微创治疗、分子靶向药物治疗和联合治疗等进行系统论述，并对上述治疗手段的优势与不足进行讨论，还就治疗方案的选择原则和个体化治疗的实施细则提出一些建设性意见，期望可为肝细胞癌併肺转移患者临床治疗方案的制订与选择提供指导，从而实现个体化治疗、以及延长患者的生存期和生活质量的目的。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	彭维忠
	秧茂盛

关键词 ：肝细胞癌, 肺转移, 治疗方案, 综述, 个体化治疗

Abstract：Hepatocellular carcinoma(HCC)is one of the world′s most common malignant tumors and pulmonary metastasis is the most common distant metastases.In the event of pulmonary metastasis,development of deterioration is rapid, which often speed up the death.In this work,the treatment of pulmonary metastases from HCC,including surgical treatment,chemotherapy drugs,radiotherapy,minimally invasive treatment,molecular targeted drug therapy and combination therapy were discussed systematically,and the advantages and disadvantages of these treatments were discussed.The constructive suggestions on the choice of treatment regimen and the implementation details of individualized therapy were presented,and hope to give out some new insights for the development and selection of clinical treatment options in patients with pulmonary metastases from HCC in order to achieve individualized treatment,improve the patient′s survival and quality of life.

Key words： Hepatocellular carcinoma Pulmonary metastase Treatment schedule Review Individualized treatment

通讯作者: 秧茂盛（1965-），男，湖南吉首人，博士，吉首大学医学院副院长，教授，生理与药理学系主讲教师，主持和参与10余项国家、省部等课题研究，发表学术论文50余篇，SCI论文20余篇，重庆市学术技术带头人

作者简介: 彭维忠（1991-），男，湖南郴州人，2015级吉首大学在读硕士研究生，研究方向：肝胆外科

引用本文:

彭维忠;秧茂盛. 肝细胞癌并肺转移的治疗研究进展[J]. 中国当代医药, 2017, 24(8): 27-30.
PENG Wei-zhong;YANG Mao-sheng. Research progress of treatment of pulmonary metastases from hepatocellular carcinoma. 中国当代医药, 2017, 24(8): 27-30.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2017/V24/I8/27

[9]	卫生部.原发性肝癌诊疗规范（2011年版）[J].临床肿瘤学杂志，2011，16（10）：929-946.
[10]	陈孝平，张志伟.肝细胞癌外科治疗相关规范与指南解读[J].临床肝胆病杂志，2013，29（1）：25-27.
[11]	张树民，曾昭冲，孙菁，等.肝细胞肝癌肺转移的预后因素分析[J].实用肿瘤杂志，2005，20（5）：395-400.
[15]	郑树森，徐骁，李建辉，等.中国肝癌肝移植临床实践指南（2014版）[J].实用器官移植电子杂志，2015，3（2）：66-71.
[25]	Lee HS.Management of patients with hepatocellular carcinoma and extrahepatic metastasis[J].Dig Dis，2011，29（3）：333-338.
[1]	Iakova P，Timchenko L，Timchenko NA.Intracellular signaling and hepatocellularcarcinoma[J].Semin Cancer Biol，2011，21（1）：28-34.
[2]	Ochiai T，Ikoma H，Okamoto K，et al.Clinicopathologic features and risk factors for extrahepatic recurrences of hepatocellular carcinoma after curative resection[J].World J Surg，2012，36（1）：136-143.
[3]	Jung SM，Jang JW，You CR，et al.Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases[J].J Gastroenterol Hepatol，2012，27（4）：684-689.
[4]	Hatzaras I，Bischof DA，Fahy B，et al.Treatment options and surveillance strategies after therapy for hepatocellular carci-noma[J].Ann Surg Oncol，2014，21（3）：758-766.
[5]	Zhong JH，Ke Y，Gong WF，et al.Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma[J].Ann Surg，2014，260（2）：329-340.
[6]	Chua TC，Morris DL.Exploring the role of resection of extrahepatic metastases from hepatocellular carcinoma[J].Surg Oncol，2012，21（2）：95-101.
[7]	Kornasiewicz O，Ligocka J，Krawczyk M.Liver resection for non-colorectal，non-endocrine liver metastasis[J].Pol Przegl Chir，2014，86（11）：544-551.
[8]	Togashi J，Sugawara Y，Aoki T，et al.Resection of lung metastases from hepatocellular carcinoma after living donor livertransplantation：reportoftwo cases[J].Surg Today，2011，41（9）：1294-1297.
[12]	Guglielmi A，Ruzzenente A，Conci S，et al.Hepatocellular carcinoma：surgical perspectives beyond the barcelona clinic liver cancer recommendations[J].World J Gastroenterol，2014，20（24）：7525-7533.
[13]	Yang T，Lin C，Zhai J，et al.Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer（BCLC）staging[J].J Cancer Res Clin Oncol，2012，138（7）：1121-1129.
[14]	Metussin A，Patanwala I，Cross TJ.Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria：a RCT[J].J Hepatol，2015，62（3）：747-748.
[27]	李焱，程朋.中晚期肝癌临床治疗进展[J].临床肝胆病杂志，2014，30（3）：233-236.
[30]	龚新雷，秦叔逵，王雅杰，等.FOLFOX4方案治疗晚期肝细胞癌的多中心Ⅱ期临床研究[J].中国新药杂志，2011，20（17）：1673-1677.
[16]	Volk M，Marrero JA.Liver transplantation for hepatocellular carcinoma：who benefits and who is harmed?[J].Gastroenterology，2008，134（5）：1612-1614.
[17]	Volk ML，Vijan S，Marrero JA.A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria[J].Am J Transplant，2008，8（4）：839-846.
[18]	Miyamura T，Yoshida R，Yagi T，et al.Successful treatment of unresectable advanced hepatoblastoma： living liver transplantation after surgical removal of lung metastasis[J]. Pediatr Transplant，2011，15（5）：E87-E91.
[19]	Xiang ZW，Sun L，Li GH，et al.Progress in the treatment of pulmonary metastases after liver transplantation for hepatocellular carcinoma[J].World J Hepatol，2015，7（20）：2309-2314.
[20]	Tomimaru Y，Sasaki Y，Yamada T，et al.The significance of surgical resection for pulmonary metastasis from hepatocellular carcinoma[J].Am J Surg，2006，192（1）：46-51.
[21]	Nakajima J，Tanaka M，Matsumoto J，et al.Appraisal of surgical treatment for pulmonary metastasis from hepatocellular carcinoma[J].World J Surg，2005，29（6）：715-718.
[22]	Lam CM，Lo CM，Yuen WK，et al.Prolonged survival in selected patients following surgical resection for pulmonary metastasis from hepatocellular carcinoma[J].Br J Surg，1998，85（9）：1198-1200.
[23]	Hwang S，Kim YH，Kim DK，et al.Resection of pulmonary metastases from hepatocellular carcinoma following liver transplantation[J].World J Surg，2012，36（7）：1592-1602.
[24]	Kitano K，Murayama T，Sakamoto M，et al.Outcome and survival analysis of pulmonary metastasectomy for hepatocellular carcinoma[J].Eur J Cardiothorac Surg，2012，41（2）：376-382.
[26]	Hau HM，Schmelzle M，Benzing C，et al.Pulmonary metastasectomy for metastasized hepatocellular carcinoma after liver resection and liver transplantation：a single center experience[J].Z Gastroenterol，2016，54（1）：31-39.
[28]	Pokorny H，Gnant M，Rasoul-Rockenschaub S，et al.Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation?[J].Am J Transplant，2005，5（4 Pt 1）：788-794.
[29]	Lee JO，Kim DY，Lim JH，et al.Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation[J].J Gastroenterol Hepatol，2009，24（5）：800-805.
[31]	Jang JW，Kay CS，You CR，et al.Simultaneous multitarget irradiation using helical tomotherapy for advanced hepato cellular carcinoma with multiple extrahepatic metastases[J]. Int J Radiat Oncol Biol Phys，2009，74（2）：412-418.
[32]	Hiraki T，Yamakado K，Ikeda O，et al.Percutaneous ra鄄diofrequency ablation for pulmonary metastases from hep鄄atocellular carcinoma：results of a multicenter study in Japan[J].J Vasc Interv Radiol，2011，22（6）：741-748.
[33]	Zhang T，Lu M，Peng S，et al.CT-guided implantation of radioactive125I seed in advanced non-small-cell lung can cer after failure of first-line chemotherapy[J].J Cancer Res Clin Oncol，2014，140（8）：1383-1390.
[34]	Kudo M，Ueshima K.Positioning of a molecular-targeted a鄄gent，sorafenib，in the treatment algorithm for hepatocellu鄄lar carcinoma and implication of many complete remission cases in Japan[J].Oncology，2010，78（Suppl 1）：154-166.
[35]	Sposito C，Mariani L，Germini A，et al.Comparative efficacy of sorafenib versus best supportive care in recurrent hepa鄄tocellular carcinoma after liver transplantation：a casecontrol study[J].J Hepatol，2013，59（1）：59-66.
[36]	Yeganeh M，Finn RS，Saab S.Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib[J].Am J Transplant，2009，9（12）：2851-2854.
[37]	Matsui Y，Ishibashi H，Ota S，et al.Bilateral pulmonary metastases from hepatocellular carcinoma successfully treated by surgical resection and stereotactic radiotherapy; report of a case[J].Kyobu Geka，2011，64（10）：944-946.
[38]	Li C，Zhang F，Zhang W，et al.Feasibility of125I brachy鄄therapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma[J].J Cancer Res Clin Oncol，2010，136（11）：1633-1640.